Last reviewed · How we verify

Epygenix — Portfolio Competitive Intelligence Brief

Epygenix pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Clemizole HCl Clemizole HCl phase 3 H1-receptor antagonist (antihistamine) Histamine H1 receptor Immunology / Allergy / Inflammation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University Hospital, Tours · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Epygenix:

Cite this brief

Drug Landscape (2026). Epygenix — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/epygenix. Accessed 2026-05-15.

Related